- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03765307
Bronchial Ablation for Treatment of Asthma (BATA) Trial (BATA)
Safety and Efficacy of the SyMap Bronchial Ablation System for Treatment of Severe Asthma: A Prospective, Multicenter, Randomized Controlled Clinical Trial (Bronchial Ablation for Treatment of Asthma (BATA) Trial)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a prospective, multicenter, randomized, clinical study comparing the SyMap bronchial radiofrequency ablation system to the Boston Scientific Bronchial Thermoplasty System (Alair System). The study population consisted of subjects with severe asthma who are still symptomatic despite being managed on high dose ICS and LABA. Patients with severe asthma who still have symptoms, despite the standard drug maintenance recommended by the guidelines, after signing the informed consent, who meet the inclusion exclusion criteria enter the baseline period and continued to use uniform ICS and LABA, which will last at least 4 weeks. Patients with at least two days asthma symptoms during the baseline period, and meet the eligibility criteria are assigned to the experimental or control group at a 1:1 ratio based on a central randomized system. A total of 160 subjects will be enrolled, 80 in the experimental group and 80 in the control group. The experimental group is treated with SyMap radiofrequency ablation system, and the control group is treated with the same procedure using Boston Scientific Bronchial Thermoplasty Aliar System. For subjects in the experimental group and the control group, follow-up by telephone call will be performed at 1, 2, 7 days after each procedure and at 1, 2, 4, 5, 7, 8, 9, 10, 11, 15, 18, 21, 27, 30, 33, 39, 42, 45, 51, 54, and 57 months after the third procedure, and outpatient follow-up will be performed at 6 weeks, 3, 6,12,24, 36, 48 and 60 months after the third procedure. ICS and LABA are administered within five years after the third procedure. The difference in the rate of severe asthma exacerbations per year (the number of severe asthma exacerbations per person per year), at 12 months after bronchial radiofrequency ablation, is the primary endpoint of the study, and the success rate of procedure, postoperative adverse events, and serious adverse events are safety endpoints.
This study is conducted by an independent clinical monitoring organization, a data management and statistical center to collect and statistically analyze all relevant clinical and laboratory data.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yue WANG, MS
- Phone Number: +13405818362
- Email: ywang@symapmedical.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Chinese PLA General Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- The First Affiliated Hospital of Guangzhou Medical University
-
Shenzhen, Guangdong, China
- University of Chinese Academy of Sciences Shenzhen Hospital
-
-
Hebei
-
Shijiazhuang, Hebei, China
- The Second Hospital of Hebei Medical University
-
Shijiazhuang, Hebei, China
- Hebei Chest Hospital
-
-
Heilongjiang
-
Qiqihar, Heilongjiang, China
- The Third Affiliated Hospital of Qiqihar Medical University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- The First Affilated Hospital with Nanjing Medical University
-
Suzhou, Jiangsu, China
- Suzhou Municipal Hospital
-
Xuzhou, Jiangsu, China
- The Affiliated Hospital of Xuzhou Medical University
-
Yangzhou, Jiangsu, China
- Northern Jiangsu People's Hospital
-
-
Liaoning
-
Shenyang, Liaoning, China
- Northern Theater Command General Hospital
-
-
Shandong
-
Yantai, Shandong, China
- Yantai Yuhuangding Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China
- Shanghai Tenth People's Hospital
-
-
Shanxi
-
Xi'an, Shanxi, China
- Tangdu Hospital, Second Affiliated Hospital of Air Force Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject is an adult between the ages of 18 to 65 years;
- Diagnosed with asthma who required regular asthma maintenance medication in the past 6 months as follows:
ICS ≥1000 μg/day beclomethasone or equivalent and LABA ≥1000μg /day salmeterol or equivalent.
Other medications were allowed, including leukotriene modifiers, and Oral Corticosteroids (OCS) ≤ 10mg/day.
- At least two days of asthma symptoms during 4-weeks of the baseline period.
- Pre-bronchodilator Forced Expiratory Volume in one second (FEV1) of greater than or equal to 45% of predicted.
- Non-smoker (less than 10 pack per year) last for 1 year or greater.
- Baseline AQLQ Score less than or equal to 6.25
- Willingness and ability to comply with the outpatient follow-up.
Exclusion Criteria:
- Pre-bronchodilator Forced Expiratory Volume in one second (FEV1) of less than 45% of predicted.
- 3 or more hospitalizations for exacerbations of asthma in the past 12 months;
- More than 3 lower respiratory tract infections requiring antibiotics in the past 12 months
- More than 4 of oral steroid use for exacerbations of asthma in the past 12 months
- Chronic sinusitis
- Uncontrolled gastroesophageal reflux disease, defined as a significant increase in treatment over the past 6 weeks
- Sensitivity to medications required to perform bronchoscopy (such as lidocaine and benzodiazepines)
- Use of an implantable electrical stimulation device, such as a pacemaker, a cardiac defibrillator or a deep nerve or deep brain stimulator;
- Severe emphysema caused by chronic obstructive pulmonary disease (COPD).
- Use of systemic immunosuppressants, beta adrenergic blockers, or anticoagulants.
- History of fatal asthma.
- Uncontrolled obstructive sleep apnea
- Intubation or admission to the ICU for asthma exacerbations within 2 years prior to treatment
- Hemorrhagic or malignant tumors or Coagulopathy.
- Lower bronchial stenosis or distal complete atelectasis or other severe bronchial and pulmonary lesions, as Thoracic spiral CT showed
- Poor compliance judged by the investigator, or other medical conditions that are not suitable for the study
- Related contraindications for bronchoscopy
- Pregnant, lactating women, or patients with a birth plan in the next year
- Previously undergone bronchial thermoplasty
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SyMap Bronchial Ablation Group
The experimental group is treated using SyMap Bronchial Radiofrequency Ablation system, including disposable bronchial radiofrequency ablation catheter (Model: BA125T) and Bronchial radiofrequency ablation instrument (Model: ELATION S3).
|
The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
|
Active Comparator: Boston Scientific Bronchial Thermoplasty Group
The control group is treated using Boston Scientific Alair System, including Bronchial radiofrequency ablation catheter Alair (Model: ATS2-5 ) and Bronchial radiofrequency ablation instrument (Model: ATS200)
|
The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of severe asthma exacerbations per year (the number of severe asthma exacerbations per person per year)
Time Frame: 12 months
|
Definition of severe asthma exacerbations:
Note: Severe asthma exacerbations of the above described two conditions, after treatment with corticosteroids, stabilized for 1 week or more, then recurring asthma symptoms will be counted as a single severe asthma exacerbations. |
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Integrated Asthma Quality of Life Questionnaire (Integrated AQLQ) Score from baseline
Time Frame: 3, 6, 12, 24, 36, 48 and 60 months
|
Asthma Quality of Life Questionnaire consists of 32 items covering asthma-related symptoms and limitations during the 2 weeks preceding administration of the questionnaire, the responses are scored on a scale of 1 to 7, with higher numbers indicating a better quality of life.
Integrated AQLQ is the average of the 6-, 9-, and 12- month scores.The proportion of subjects within each group that achieved an AQLQ score change of 0.5 or greater is analyzed.
|
3, 6, 12, 24, 36, 48 and 60 months
|
Asthma Quality of Life Questionnaire Score (AQLQ)
Time Frame: 6 weeks, 3, 6, 12, 24, 36, 48 and 60months
|
Asthma Quality of Life Questionnaire consists of 32 items covering asthma-related symptoms and limitations during the 2 weeks preceding administration of the questionnaire, the responses are scored on a scale of 1 to 7, with higher numbers indicating a better quality of life.
|
6 weeks, 3, 6, 12, 24, 36, 48 and 60months
|
Modified Asthma Control Questionnaire (ACQ-6) Score
Time Frame: 6 weeks, 3, 6, 12, 24, 36, 48 and 60months
|
Modified Asthma Control Questionnaire (ACQ-6) Consists of six questions (1 for bronchodilator use and 5 for asthma symptoms).
The scores range from 0 (full control) to 6 (seriously uncontrolled).
The ACQ-6 average score is the mean of the patient score.
The average score ≤ 0.75 indicates that the asthma control is good, 0.75 ~ ≤ 1.5 prompts partial control, > 1.5 prompts poor control.
The proportion of subjects within each group that achieved an AQLQ score change of 0.5 or greater was analyzed.
|
6 weeks, 3, 6, 12, 24, 36, 48 and 60months
|
Percent of Symptom-Free Days
Time Frame: 12 months
|
12 months
|
|
Numbers of severe asthma exacerbations
Time Frame: 6 weeks, 12, 24, 36, 48 and 60 months
|
6 weeks, 12, 24, 36, 48 and 60 months
|
|
Forced Expiratory Volume in one second (FEV1)
Time Frame: 6 weeks, 12, 24, 36, 48 and 60months
|
6 weeks, 12, 24, 36, 48 and 60months
|
|
Peak expiratory flow (PEF)
Time Frame: 6 weeks, 12 , 24, 36, 48 and 60 months
|
6 weeks, 12 , 24, 36, 48 and 60 months
|
|
Rate of severe asthma exacerbations per year
Time Frame: 24, 36, 48 and 60 months
|
the number of severe asthma exacerbations per person per year
|
24, 36, 48 and 60 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absence of work/school due to asthma symptoms, or days affecting daily actives
Time Frame: 12 months
|
12 months
|
|
Emergency Room Visits days
Time Frame: 12, 24, 36, 48 and 60 months
|
12, 24, 36, 48 and 60 months
|
|
Hospitalization days
Time Frame: 12, 24, 36, 48 and 60 months
|
12, 24, 36, 48 and 60 months
|
|
Successful rate of procedure
Time Frame: During the procedure
|
defned by whether the catheter can be engaged in the correct position in the bronchus to successfully complete the bronchial radiofrequency ablation
|
During the procedure
|
Safety of the procedure
Time Frame: During the procedure
|
related adverse events and complications during the procedure
|
During the procedure
|
Adverse events (AEs), serious adverse events (SAEs) after procedure
Time Frame: 1, 2 days, and 7 days after procedure
|
1, 2 days, and 7 days after procedure
|
|
Rate of Adverse events (AEs), serious adverse events (SAEs)
Time Frame: 6 weeks, 3, 6, 12, 24, 36, 48 and 60 months
|
6 weeks, 3, 6, 12, 24, 36, 48 and 60 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Shiyue Li, MD, The First Affiliated Hospital of Guangzhou Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201801
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on SyMap Bronchial Ablation System
-
Boston Scientific CorporationCompletedAsthmaSpain, Italy, Germany, Netherlands, Australia, Czechia, South Africa, United Kingdom
-
Boston Scientific CorporationCompleted
-
University Hospital, Strasbourg, FranceUnknown
-
Boston Scientific CorporationCompletedAsthmaCanada, Brazil, United Kingdom
-
Boston Scientific CorporationCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Boston Scientific Corporation; ZonMw: The Netherlands Organisation for Health... and other collaboratorsCompletedAsthma | Bronchial AsthmaNetherlands, United Kingdom
-
Gala Therapeutics, Inc.Active, not recruiting
-
University Hospital, BordeauxInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingAsthma in ChildrenFrance